Some people need a higher dose to prevent weight regain, while others are able to come down to a much lower dose
is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire obesity-drug developer Metsera
Contact your provider if you want to discuss switching medications
Everything arrived in perfect condition
Wilson PW, DAgostino RB, Sullivan L, Parise H, Kannel WB
Funding Writing and editorial assistance was provided to the authors by Dr Timothy Ryder from Biological Communications Limited (London, United Kingdom) and funded by Allergan Aesthetics, an AbbVie company (Irvine, CA)